Cytek Biosciences (CTKB) Receivables (2020 - 2026)

Cytek Biosciences has reported Receivables for 7 years, with the latest figure at $51.9 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 5.68% year-over-year to $51.9 million; the trailing twelve-month figure through Mar 2026 stood at $51.9 million (down 5.68% YoY), and the FY2025 full-year result was $62.5 million, up 3.17% from the prior year.
• Receivables for Q1 2026 stood at $51.9 million, down from $62.5 million in the prior quarter.
• The five-year high for Receivables was $62.5 million in Q4 2025, with the low at $32.0 million in Q1 2022.
• Historically, Receivables has averaged $50.1 million across 5 years, with a median of $51.9 million in 2026.
• Annual changes were most pronounced in 2022 — Receivables surged 64.19% — and 2024, when it dropped 10.04%.
• Cytek Biosciences' Receivables stood at $48.9 million in 2022, then advanced by 14.46% to $55.9 million in 2023, then gained by 8.33% to $60.6 million in 2024, then advanced by 3.17% to $62.5 million in 2025, then decreased by 16.97% to $51.9 million in 2026.
• The last three Receivables figures came in at $51.9 million (Q1 2026), $62.5 million (Q4 2025), and $56.6 million (Q3 2025), per Business Quant data.